[APPY] Venaxis, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.94 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart APPY

Refresh chart

Description: Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. The company?s research and development activities primarily focus on a human acute appendicitis blood-based test. Its lead product candidate includes APPY1, a novel blood-based diagnostic test designed to aid in the evaluation of patients for acute appendicitis. Venaxis, Inc., through its license agreement with Washington University in St. Louis, develops, markets, sells, distributes, imports, and exports luteinizing hormone and/or follicle-stimulating hormone products for bovine, equine, and swine animals. The company was formerly known as AspenBio Pharma, Inc. and changed its name to Venaxis, Inc. in December 2012. Venaxis, Inc. was founded in 2000 and is based in Castle Rock, Colorado.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.71 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 45.83% Sales Growth - Q/Q-66.02% P/E-2.47
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-37.03% ROE-44.15% ROI
Current Ratio21.99 Quick Ratio Long Term Debt/Equity0.09 Debt Ratio0.05
Gross Margin Operating Margin-4374.77% Net Profit Margin-4361.26% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-130 K Cash From Investing Activities3.08 M Cash From Operating Activities-2.29 M Gross Profit10 K
Net Profit-2.19 M Operating Profit-2.21 M Total Assets26.14 M Total Current Assets22.36 M
Total Current Liabilities1.02 M Total Debt2.18 M Total Liabilities4.21 M Total Revenue10 K
Technical Data
High 52 week4.54 Low 52 week1.6 Last close3.94 Last change-0.25%
RSI71.48 Average true range0.5 Beta0.82 Volume
Simple moving average 20 days20.1% Simple moving average 50 days36.16% Simple moving average 200 days26.72%
Performance Data
Performance Week-2.72% Performance Month56.35% Performance Quart-4.14% Performance Half19.03%
Performance Year53.91% Performance Year-to-date64.17% Volatility daily8.99% Volatility weekly20.11%
Volatility monthly41.21% Volatility yearly142.77% Relative Volume0% Average Volume84.3 K
New High New Low

News

2017-01-23 11:47:53 | Colorado biotech cutting employees, exploring 'strategic alternatives'

2016-12-12 16:54:04 | BIOPTIX, INC. Files SEC form 8-K, Other Events

2016-12-08 16:31:00 | 4:31 pm Venaxis's name has been changed to Bioptix and the trading symbol will change to _BIOP_ effective at the opening of trading on December 12, 2016

2016-12-08 16:30:00 | Venaxis Reports Name Change to Bioptix, Inc and NASDAQ Ticker Symbol Change to _BIOP_ from _APPY_

2016-12-02 09:10:04 | BIOPTIX, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Secur

2016-11-30 17:14:24 | VENAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure

2016-11-18 11:25:29 | Venaxis, Inc. :APPY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016

2016-11-14 17:43:03 | VENAXIS, INC. Files SEC form 10-Q, Quarterly Report

2016-09-27 17:01:56 | VENAXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers

2016-09-23 10:12:02 | Venaxis Reports Option Inducement Grants for New Employees Under NASDAQ Listing Rule 5635c4

2016-09-23 08:00:00 | Venaxis Reports Option Inducement Grants for New Employees Under NASDAQ Listing Rule 5635c4

2016-09-20 09:00:00 | Venaxis Issues Shareholder Update

2016-09-19 20:18:03 | Venaxis Issues Shareholder Update

2016-09-19 16:57:24 | VENAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure

2016-09-14 12:37:26 | VENAXIS, INC. Files SEC form 8-K, Other Events

2016-09-13 17:18:01 | Venaxis Announces Acquisition of BiOptix

2016-09-13 17:11:42 | VENAXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement

2016-09-13 17:00:00 | Venaxis Announces Acquisition of BiOptix

2016-08-24 07:08:00 | 7 Stocks Under $10 Making Big Up Moves

2016-08-23 13:04:33 | VENAXIS, INC. Financials

2016-08-10 16:52:41 | VENAXIS, INC. Files SEC form 10-Q, Quarterly Report

2016-05-18 12:31:00 | MGT Stock Falls From 3 1/2-Year High

2016-05-11 08:43:40 | VENAXIS, INC. Files SEC form 10-Q, Quarterly Report

2016-04-14 16:39:00 | VENAXIS, INC. Files SEC form 8-K, Other Events

2016-04-04 09:01:02 | VENAXIS, INC. Files SEC form 8-K, Other Events

2016-03-30 13:01:03 | VENAXIS, INC. Files SEC form 8-K, Other Events

2016-03-29 16:21:18 | VENAXIS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statemen

2016-03-29 13:05:13 | Venaxis, Inc. :APPY-US: Earnings Analysis: Q4, 2015 By the Numbers

2016-03-29 12:24:12 | Venaxis, Inc. :APPY-US: Earnings Analysis: 2015 By the Numbers

2016-03-23 16:37:03 | VENAXIS, INC. Files SEC form 10-K, Annual Report

2016-03-14 17:03:13 | VENAXIS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement

2015-11-30 09:57:40 | Venaxis, Inc. Earnings Q3, 2015

2015-10-23 14:01:34 | Venaxis, Inc. – Value Analysis NASDAQ:APPY : October 23, 2015

2015-04-02 13:28:00 | 3 Stocks Under $10 Triggering Breakout Trades